MU has launched its first clinical trial using reactor-made Eye90 microspheres to target inoperable liver tumors with precision radiotherapy.

Eli Lilly’s oral targeted cancer therapy, Retevmo, has shown benefit as an adjunctive therapy in a Phase III trial in ...

During a live event, Hagen Kennecke, MD, discusses how RADIANT-4 and NETTER trials have reshaped NET care with everolimus and ...

HER2-positive cancers overexpress the human epidermal growth factor receptor 2. When expressed at abnormally high levels, HER2 leads to uncontrolled cell growth and a more aggressive behavior than ...

New trials target hard-to-treat cancers with more personalized, less toxic therapies, including pediatric brain tumors, colorectal, ovarian, bladder cancers, and leukemia. FDA cleared Reyobiq for ...

Japanese patient cohort enrollment is completed ahead of schedule at multiple clinical sites including the National Cancer Center in Tokyo The incidence rate of never-smokers with non-small cell lung ...

A new clinical trial finds that people with a limited number of metastases from recurrent prostate cancer lived significantly longer without disease progression when they received a ...

Doctors at Boston’s Beth Israel share how CAR T cell therapy and other emerging immune therapies are delivering promising ...

DALLAS--(BUSINESS WIRE)-- Lantern Pharma Inc. (NASDAQ: LTRN), an artificial intelligence (AI) company developing targeted cancer therapies using its proprietary RADR® AI platform, today announced the ...